Switch Language
Alt tag

Thrombosis Adviser
for Healthcare Professionals

Join more than 1.500 of your peers to stay up to date with the latest in thrombosis.

Sign up now!

Subscribe

See Also

Alt tag Alt tag

Peripheral Artery Disease: causes and consequences

Alt tag Alt tag

Coronary Artery Disease: causes and consequences

Thrombosis Digest 2022

ESC 2022 Congress Highlights

ESC 2022 Congress Highlights

ESC 2022 Congress Highlights

ESC 2022 Congress Highlights ESC 2022 Congress Highlights

2022-10-10

The annual European Society of Cardiology (ESC) congress took place on 26-29 August 2022 in Barcelona, Spain. Delegates were able to attend both virtually and in-person.

 

Read more

International Society on Thrombosis and Haemostasis (ISTH) Congress 2022 Newsletter

International Society on Thrombosis and Haemostasis (ISTH) Congress 2022 Newsletter

International Society on Thrombosis and Haemostasis (ISTH) Congress 2022 Newsletter

International Society on Thrombosis and Haemostasis (ISTH) Congress 2022 Newsletter International Society on Thrombosis and Haemostasis (ISTH) Congress 2022 Newsletter

2022-09-06

The year 2022 marked the return of the International Society on Thrombosis and Haemostasis (ISTH) congress to an in-person format. The meeting took place at the ExCel Centre in London, UK from 9 to 13 July. Although many of the sessions were available through their online platform, ISTH 2022 saw around 6500 in-person attendees from all over the world.

 

Read more

International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) 2022

International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) 2022

International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) 2022

International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) 2022 International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) 2022

2022-06-28

The 2022 edition of the International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) took place from 27–29 May as a hybrid meeting, both in-person in Bergamo, Italy, and online through the virtual platform. Approximately 300 people attended the congress in person, with a further 150 joining online.

 

Read more

Your older patients with atrial fibrillation: Are you missing the broader picture?

Your older patients with atrial fibrillation: Are you missing the broader picture?

Your older patients with atrial fibrillation: Are you missing the broader picture?

Your older patients with atrial fibrillation: Are you missing the broader picture? Your older patients with atrial fibrillation: Are you missing the broader picture?

2022-06-14

Archie is 70 years old and has recently retired after working for 33 years as a civil engineer. For several years he has been eagerly looking forward to spending more time with his four young grandchildren. He has a history of hypertension but is otherwise well. Following several recent episodes of feeling faint and dizzy, he was diagnosed with non-valvular atrial fibrillation (NVAF). After discussion with his doctor, the decision was made to start anticoagulation.

 

Read more

EHRA 2022 Congress Highlights

EHRA 2022 Congress Highlights

EHRA 2022 Congress Highlights

EHRA 2022 Congress Highlights EHRA 2022 Congress Highlights

2022-06-07

The annual European Heart Rhythm Association (EHRA) congress took place on 3–5 April 2022, with delegates attending both virtually and in-person once again in Copenhagen, Denmark. Atrial fibrillation (AF) is the most prevalent sustained cardiac arrythmia in the world1 and, as such, was a main topic of discussion in the scientific programme of EHRA, the leading network of European cardiac rhythm management specialists.

 

Read more

Extended treatment for recurrent VTE: Protecting your patients for as long as they need

Extended treatment for recurrent VTE: Protecting your patients for as long as they need

Extended treatment for recurrent VTE: Protecting your patients for as long as they need

Extended treatment for recurrent VTE: Protecting your patients for as long as they need Extended treatment for recurrent VTE: Protecting your patients for as long as they need

2022-03-01

Max is 40 years old and loves to snowboard regularly, with the ambition of becoming a snowboarding instructor. Max has been a habitual smoker since he was 25 years old. Just over 2 years ago, he experienced a deep vein thrombosis (DVT) and was prescribed rivaroxaban. He stopped anticoagulation treatment after 6 months. During this time, Max quit smoking; however, 6 months after he stopped treatment, he had another DVT event and was prescribed rivaroxaban again. After this event, Max was tested and diagnosed with a homozygous Factor V Leiden mutation. Now a decision needs to be made whether to continue his anticoagulation treatment, but Max is worried that anticoagulation will get in the way of his life. 

 

How can Max get the best protection from venous thromboembolism (VTE) with a treatment regimen that fits his lifestyle?

Read more

The use of NOACs in the extended management of cancer‑associated thrombosis

The use of NOACs in the extended management of cancer‑associated thrombosis

The use of NOACs in the extended management of cancer‑associated thrombosis

The use of NOACs in the extended management of cancer‑associated thrombosis The use of NOACs in the extended management of cancer‑associated thrombosis

2022-03-01

Just a year after meeting her first grandchild, Claire received a lung cancer diagnosis. She was forced to give up her hobby as a frequent hiker and struggled to stay active due to the burdens of her treatment; Claire later developed a deep vein thrombosis (DVT). For the treatment of her DVT, Claire was prescribed rivaroxaban because she expressed a preference for an oral anticoagulant. Six months have passed, and Claire has not experienced a recurrent DVT nor any adverse events. A decision is now needed on whether she requires extended anticoagulation to reduce the risk of recurrent venous thromboembolism (VTE) or if treatment can be safely discontinued.

Read more

Protecting elderly patients with atrial fibrillation

Protecting elderly patients with atrial fibrillation

Protecting elderly patients with atrial fibrillation

Protecting elderly patients with atrial fibrillation Protecting elderly patients with atrial fibrillation

2021-12-14

Monica is 82 years old, loves to travel and has been planning her dream holiday in the Caribbean with her new partner, Lionel. She leads a busy life, regularly volunteering at a suicide prevention helpline and frequently visiting family and friends.

 

She was diagnosed with type 2 diabetes last year after routine blood tests performed by her GP found a high serum glucose. While at her primary care centre for a diabetes review, she mentioned occasional palpitations to the practice nurse who performed a 12-lead ECG, diagnosing atrial fibrillation (AF).

 

Considering her age and comorbid diabetes, how would you approach Monica from the perspective of managing her AF?

Read more

Copyright © Bayer AG |

Updated date 10/10/2022

This website is intended to provide information to an international audience outside the USA and UK.

Copyright © Bayer AG |

Updated date 10/10/2022

This website is intended to provide information to an

international audience outside the USA and UK.

Bayer Bayer

Follow us